PMEL and metastatic melanoma: Vaccine regimens incorporating high dose IL-2 as an immune modulator to the melanoma gp100 TAA peptide showed regression of B16 melanoma tumors in mice and increased objective responses in patients with metastatic melanoma as compared to IL-2 or gp100 monotherapy (100, 105–108).